Rafferty Asset Management
ARCT icon

Rafferty Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Rafferty Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,050
Closed -$664K – 1135
2025
Q3 		$664K Sell
36,050
-1,596
-4% -$25.6K ﹤0.01% 858
2025
Q2 		$490K Sell
37,646
-11,837
-24% -$140K ﹤0.01% 895
2025
Q1 		$524K Sell
49,483
-8,109
-14% -$129K ﹤0.01% 854
2024
Q4 		$977K Sell
57,592
-7,628
-12% -$144K ﹤0.01% 798
2024
Q3 		$1.51M Sell
65,220
-12,794
-16% -$274K 0.01% 706
2024
Q2 		$1.9M Sell
78,014
-78,579
-50% -$2.38M 0.01% 656
2024
Q1 		$5.29M Buy
156,593
+43,421
+38% +$1.54M 0.02% 465
2023
Q4 		$3.57M Sell
113,172
-19,609
-15% -$466K 0.02% 514
2023
Q3 		$3.39M Sell
132,781
-25,704
-16% -$792K 0.02% 476
2023
Q2 		$4.55M Sell
158,485
-47,989
-23% -$1.31M 0.03% 438
2023
Q1 		$4.95M Sell
206,474
-2,780
-1% -$49.9K 0.03% 387
2022
Q4 		$3.55M Sell
209,254
-51,726
-20% -$902K 0.03% 451
2022
Q3 		$3.87M Buy
260,980
+60,794
+30% +$1.02M 0.04% 377
2022
Q2 		$3.15M Sell
200,186
-102,004
-34% -$2M 0.03% 378
2022
Q1 		$8.15M Buy
302,190
+81,784
+37% +$2.09M 0.05% 224
2021
Q4 		$8.16M Buy
220,406
+61,523
+39% +$2.51M 0.04% 233
2021
Q3 		$7.59M Sell
158,883
-27,946
-15% -$1.25M 0.05% 216
2021
Q2 		$6.32M Buy
186,829
+119,483
+177% +$4.04M 0.04% 267
2021
Q1 		$2.78M Buy
67,346
+58,551
+666% +$3.49M 0.02% 537
2020
Q4 		$382K Sell
8,795
-42,609
-83% -$2.89M ﹤0.01% 747
2020
Q3 		$2.21M Buy
+51,404
New +$2.55M 0.03% 384

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Rafferty Asset Management's ARCT Position: Q4 2025 in Review

Rafferty Asset Management sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 36,050 shares — an estimated $664K sold.

Rafferty Asset Management first reported a position in ARCT in Q3 2020 and held it in 21 quarters. The position peaked at $8.16M in Q4 2021. 121 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Rafferty Asset Management reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rafferty Asset Management sold 36,050 Arcturus Therapeutics shares in Q4 2025, an estimated $664K.
  • Rafferty Asset Management first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 21 quarters.
  • Rafferty Asset Management's Arcturus Therapeutics position peaked at $8.16M in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Rafferty Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.